Sanofi, Regeneron reports cSCC data for PD-1 inhibitor cemiplimab

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported top-line data from 82 evaluable patients with advanced cutaneous squamous cell carcinoma (cSCC) in the pivotal Phase II

Read the full 284 word article

User Sign In